While our study offers evidence that JYBP alleviates MG by inhibiting the differentiation of CD4+ T cells into Th17 cells through the TAK1/P38 MAPK/eIF-4E signaling pathway, several limitations should be noted. This evidence concerns the gene MAP3K7 and myasthenia gravis.